Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Fresh Versus Cryopreserved/Thawed Bispecific Anti-CD19/CD20 CAR-T Cells for Relapsed, Refractory Non-Hodgkin Lymphoma

Nirav N. Shah, MD, Fenlu Zhu, PhD, Dina Schneider, PhD, Winfried Krueger, Andrew Worden, Walter L. Longo, MD, Mehdi Hamadani, MD, Timothy S. Fenske, MD, Boro Dropulic, PhD, Rimas J Orentas, PhD, Parameswaran Hari, MBBS, MD, Bryon Johnson, PhD

Blood (2019) 134 (Supplement_1): 4465.

https://doi.org/10.1182/blood-2019-125328

Published: 2019

Journal Articles

Point-of-Care Manufacturing of CD20.19 Bi-Specific Chimeric Antigen Receptor T (CAR-T) Cells in a Standard Academic Cell Processing Facility for a Phase I Clinical Trial in Relapsed, Refractory NHL

Fenlu Zhu, PhD, Nirav N Shah, MD, Dina Schneider, PhD, Huiqing Xu, MD, Katherine Chaney, MS, Lawrence Luib, MS, Carolyn A. Keever-Taylor, DPhil, Boro Dropulic, PhD, Rimas Orentas, PhD, Parameswaran Hari, MBBS, MD, Bryon Johnson, PhD

Blood (2018) 132 (Supplement 1): 4553.

https://doi.org/10.1182/blood-2018-99-116566

Published: 2018

Journal Articles

A Phase 1 Study with Point-of-Care Manufacturing of Dual Targeted, Tandem Anti-CD19, Anti-CD20 Chimeric Antigen Receptor Modified T (CAR-T) Cells for Relapsed, Refractory, Non-Hodgkin Lymphoma

Nirav N Shah, MD, Fenlu Zhu, PhD, Carolyn Taylor, PhD, Dina Schneider, PhD, Winfried Krueger, Andrew Worden, Sharon Yim, Timothy S. Fenske, MD, Mehdi Hamadani, MD, Bryon Johnson, PhD, Boro Dropulic, PhD, Rimas Orentas, PhD, Parameswaran Hari, MBBS, MD

Blood (2018) 132 (Supplement 1): 4193.

https://doi.org/10.1182/blood-2018-99-110194

Published: 2018

Journal Articles

Pilot Study of Prognostic Impact of Pre-Allogeneic Hematopoietic Cell Transplantation (HCT) Plasma Levels of CXC-Chemokines (CXCL-4 and CXCL-7) in Patients with Myelodysplastic Syndromes (MDS)

Binod Dhakal, MD MS, Tao Wang, PhD, Michael D Haagenson, MS, Fenlu Zhu, PhD, Carolyn A. Keever-Taylor, PhD, Stephen R. Spellman, MBS, Michael R. Verneris, MD, Katharine C. Hsu, MD PhD, Katharina Fleischhauer, MD, Stephanie J. Lee, MD, Wael Saber, MD MS

Blood (2016) 128 (22): 4678.

https://doi.org/10.1182/blood.V128.22.4678.4678

Published: 2016

Journal Articles

CAR-T Cell Production Using the Clinimacs ® Prodigy System

Fenlu Zhu, PhD, Nirav N. Shah, MD MSHP, Huiqing Xu, MD, Dina Schneider, Rimas Orentas, PhD, Boro Dropulic, Parameswaran Hari, MD MRCP, MS, Carolyn A. Keever-Taylor, PhD

Blood (2016) 128 (22): 5724.

https://doi.org/10.1182/blood.V128.22.5724.5724

Published: 2016

Journal Articles

Day 100 Absolute Lymphocyte Count (ALC) Predicts Risk of Serious Infections in Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation (HCT)

Arun Singavi, MD, Jonathan Kapke, DO, Adam Levin, MD, Anjishnu Banerjee, PhD, Fenlu Zhu, PhD, Mehdi Hamadani, MD, Parameswaran Hari, MD MRCP, MS, Timothy S. Fenske, MD

Blood (2015) 126 (23): 3168.

https://doi.org/10.1182/blood.V126.23.3168.3168

Published: 2015

Journal Articles

Generation of Multi-Specific CTL Lines Using Overlapping Pentadecapeptide Pools of Aspergillus f16 and Adenovirus Hexon Antigens Presented on Epstein Barr Virus-Transformed B Cells as Antigen Presenting Cells.

Fenlu Zhu, PhD, Barbara Davies, B.S., David A. Margolis, M.D., Carolyn A. Keever-Taylor, Ph.D.

Blood (2006) 108 (11): 2927.

https://doi.org/10.1182/blood.V108.11.2927.2927

Published: 2006

NARROW

Fresh Versus Cryopreserved/Thawed Bispecific Anti-CD19/CD20 CAR-T Cells for Relapsed, Refractory Non-Hodgkin Lymphoma

Point-of-Care Manufacturing of CD20.19 Bi-Specific Chimeric Antigen Receptor T (CAR-T) Cells in a Standard Academic Cell Processing Facility for a Phase I Clinical Trial in Relapsed, Refractory NHL

A Phase 1 Study with Point-of-Care Manufacturing of Dual Targeted, Tandem Anti-CD19, Anti-CD20 Chimeric Antigen Receptor Modified T (CAR-T) Cells for Relapsed, Refractory, Non-Hodgkin Lymphoma

Pilot Study of Prognostic Impact of Pre-Allogeneic Hematopoietic Cell Transplantation (HCT) Plasma Levels of CXC-Chemokines (CXCL-4 and CXCL-7) in Patients with Myelodysplastic Syndromes (MDS)

CAR-T Cell Production Using the Clinimacs ® Prodigy System

Day 100 Absolute Lymphocyte Count (ALC) Predicts Risk of Serious Infections in Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation (HCT)

Generation of Multi-Specific CTL Lines Using Overlapping Pentadecapeptide Pools of Aspergillus f16 and Adenovirus Hexon Antigens Presented on Epstein Barr Virus-Transformed B Cells as Antigen Presenting Cells.

Email alerts

ASH Publications

American Society of Hematology

Fresh Versus Cryopreserved/Thawed Bispecific Anti-CD19/CD20 CAR-T Cells for Relapsed, Refractory Non-Hodgkin Lymphoma

Point-of-Care Manufacturing of CD20.19 Bi-Specific Chimeric Antigen Receptor T (CAR-T) Cells in a Standard Academic Cell Processing Facility for a Phase I Clinical Trial in Relapsed, Refractory NHL

A Phase 1 Study with Point-of-Care Manufacturing of Dual Targeted, Tandem Anti-CD19, Anti-CD20 Chimeric Antigen Receptor Modified T (CAR-T) Cells for Relapsed, Refractory, Non-Hodgkin Lymphoma

Pilot Study of Prognostic Impact of Pre-Allogeneic Hematopoietic Cell Transplantation (HCT) Plasma Levels of CXC-Chemokines (CXCL-4 and CXCL-7) in Patients with Myelodysplastic Syndromes (MDS)

CAR-T Cell Production Using the Clinimacs ® Prodigy System

Day 100 Absolute Lymphocyte Count (ALC) Predicts Risk of Serious Infections in Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation (HCT)

Generation of Multi-Specific CTL Lines Using Overlapping Pentadecapeptide Pools of Aspergillus f16 and Adenovirus Hexon Antigens Presented on Epstein Barr Virus-Transformed B Cells as Antigen Presenting Cells.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only